Items where authors include "Stilgenbauer, S"

Article

Barrientos, JC, Hillmen, P orcid.org/0000-0001-5617-4403, Salles, G et al. (8 more authors) (2020) No increased bleeding events in patients with relapsed chronic lymphocytic leukemia and indolent non-Hodgkin lymphoma treated with idelalisib. Leukemia & Lymphoma. ISSN 1042-8194

Tausch, E, Beck, P, Schlenk, RF et al. (18 more authors) (2020) Prognostic or predictive role of gene mutations in chronic lymphocytic leukemia: results from the pivotal phase III study COMPLEMENT1. Haematologica: the hematology journal, 105 (10). pp. 2440-2447. ISSN 0390-6078

Davids, MS, Kuss, BJ, Hillmen, P orcid.org/0000-0001-5617-4403 et al. (13 more authors) (2020) Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL in the DUO Crossover Extension Study. Clinical Cancer Research. ISSN 1078-0432

Flinn, IW, Hillmen, P orcid.org/0000-0001-5617-4403, Montillo, M et al. (22 more authors) (2018) The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL. Blood, 132 (23). pp. 2446-2455. ISSN 0006-4971

Buehler, A, Wendtner, C-M, Kipps, TJ et al. (17 more authors) (2016) Lenalidomide treatment and prognostic markers in relapsed or refractory chronic lymphocytic leukemia: data from the prospective, multicenter phase-II CLL-009 trial. Blood Cancer Journal, 6. ARTN e404. ISSN 2044-5385